AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients. We added rituximab, reduced and/or rescheduled cyclo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Noy, Ariela, Lee, Jeannette Y., Cesarman, Ethel, Ambinder, Richard, Baiocchi, Robert, Reid, Erin, Ratner, Lee, Wagner-Johnston, Nina, Kaplan, Lawrence
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497960/
https://ncbi.nlm.nih.gov/pubmed/25957391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-623900
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados